Generic Exclusivity Battles Now Extend To Brand-Authorized Versions: Mylan Blocks Launch Of Apotex's Paxil CR Copy
This article was originally published in The Pink Sheet Daily
Executive Summary
A court issued a temporary restraining order against Apotex and GlaxoSmithKline in response to Mylan's claims that it has sole rights to market generic Paxil CR under a licensing agreement with GSK.
You may also be interested in...
Mylan Launches Generic Paxil CR
Launch includes 180-day exclusivity for 12.5 mg and 25 mg paroxetine tablets, and follows patent settlement with GSK last year.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.